REG - Spectral MD Holdings - Grant of Options

Spectral MD HoldingsAnnouncement

19/08/2022 09:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220819:nRSS6083Wa&default-theme=true

RNS Number : 6083W  Spectral MD Holdings, Ltd.  19 August 2022

 

Spectral MD Holdings, Ltd

("Spectral MD" or the "Company" or the "Group")

 

Grant of Options

 

LONDON, U.K AND DALLAS, TX, U.S. - Spectral MD Holdings, Ltd. (AIM: SMD), a
predictive analytics company that develops proprietary AI algorithms and
optical technology for faster and more accurate treatment decisions in wound
care, announces that it has granted options ("Options") over a total of
1,080,000  common stock of US$0.001 ("Common Stock") in the Company
("Shares") to various new employees of the Company in accordance with the
Company's 2018 Long Term Incentive Plan. The Options vest over a three-year
period from the date of grant, expire after ten years and have an exercise
price of 35.5 pence.

 For further information, please contact:

 Spectral MD Holdings, Ltd.                                                                          https://investors.spectralmd.com/ (https://investors.spectralmd.com/)
 Wensheng Fan, Chief Executive Officer                                                               via Walbrook PR

 Nils Windler, Chief Financial Officer

 SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)                                 +44 (0) 20 3470 0470
 Stuart Gledhill / Caroline Rowe (Corporate Finance)

 Vadim Alexandre / Rob Rees (Sales and Corporate Broking)
 Stifel Nicolaus Europe Limited (Joint Broker)                                                       +44 (0) 20 7710 7600
 Charles Hoare / Ben Maddison / Will Palmer-Brown

 Walbrook PR Ltd (Media & Investor Relations)      +44 (0)20 7933 8780 or spectralMD@walbrookpr.com
 Sam Allen / Alice Woodings                                                 +44 (0)75 0255 8258 / +44 (0) 7407 804654

About Spectral MD:

We are a dedicated team of forward-thinkers striving to revolutionize the
management of wound care by "Seeing the Unknown" ® with
our DeepView(®) Wound Imaging System.

www.spectralmd.com

info@spectralmd.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHGIGDIBBBDGDC